Profile data is unavailable for this security.
About the company
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
- Revenue in USD (TTM)0.00
- Net income in USD-63.42m
- Incorporated2005
- Employees79.00
- LocationVerona Pharma PLCRiverside, 3 More London PlaceLONDON SE1 2REUnited KingdomGBR
- Phone+44 203 283 4200
- Fax+44 207 863 3314
- Websitehttps://www.veronapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyra Biosciences Inc | 0.00 | -75.45m | 929.43m | 49.00 | -- | 2.38 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 933.92m | 150.00 | -- | 5.11 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 955.38m | 284.00 | -- | 4.69 | -- | 11.81 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 999.54m | 309.00 | -- | 1.34 | -- | 28.29 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Liquidia Corp | 15.97m | -107.69m | 1.00bn | 136.00 | -- | 11.61 | -- | 62.81 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Innoviva Inc | 311.59m | 181.39m | 1.00bn | 112.00 | 7.34 | 1.43 | 4.57 | 3.22 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Verona Pharma PLC - ADR | 0.00 | -63.42m | 1.02bn | 79.00 | -- | 4.53 | -- | -- | -0.7907 | -0.7907 | 0.00 | 2.78 | 0.00 | -- | -- | 0.00 | -20.69 | -31.31 | -22.18 | -34.77 | -- | -- | -- | -702.82 | -- | -- | 0.1775 | -- | -100.00 | -- | 20.86 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.03bn | 267.00 | -- | -- | -- | 2.49 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 1.06bn | 29.00 | -- | 12.17 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Pharvaris NV | 0.00 | -114.99m | 1.07bn | 82.00 | -- | 2.77 | -- | -- | -2.57 | -2.57 | 0.00 | 7.22 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.08bn | 46.00 | -- | 3.37 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Silence Therapeutics plc | 33.58m | -44.43m | 1.08bn | 115.00 | -- | 6.20 | -- | 32.27 | -0.3904 | -0.3904 | 0.2851 | 1.13 | 0.1829 | -- | 5.37 | 291,970.60 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Data as of May 22 2024. Currency figures normalised to Verona Pharma PLC's reporting currency: US Dollar USD
37.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 6.32m | 8.16% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 3.91m | 5.05% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 3.76m | 4.86% |
| Deep Track Capital LPas of 31 Mar 2024 | 3.19m | 4.12% |
| Octagon Capital Advisors LPas of 31 Mar 2024 | 2.37m | 3.06% |
| Federated Global Investment Management Corp.as of 31 Mar 2024 | 2.26m | 2.92% |
| Eventide Asset Management LLCas of 31 Mar 2024 | 2.19m | 2.83% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 2.03m | 2.62% |
| Maverick Capital Ltd.as of 31 Mar 2024 | 1.78m | 2.29% |
| Jennison Associates LLCas of 31 Mar 2024 | 1.59m | 2.06% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
